Program
baxdrostat
Also written as “Baxdrostat”, “CIN-107” and “Baxdrostat/dapagliflozin”.
Its studies are mostly in Hypertension · Renal Insufficiency, Chronic · Hyperaldosteronism · Heart Failure · Atherosclerosis, led by 2 companies.
Drug pageBaxdrostat: every studyAll 28 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZenecaits history only | 256 open or running | phase 3since Sep 6, 2023 | Aug 17, 2020 | Dec 10, 2026phase 2 · NCT07222917 |
| Hoffmann-La Roche | 10 open or running | phase 1since Nov 20, 2013 | Nov 20, 2013 | none ahead |
Also a collaborator on its studies: Tigermed Consulting and Parexel.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Hoffmann-La Roche only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Nov 20, 2013First study: phase 1 study in AtherosclerosisFirst studyNCT01995383 · 88 enrolled · United States
- Jul 28, 2021Named baxdrostatINNProposed as its International Nonproprietary Name in WHO's List 125 · before, CIN-107, RO6836191
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
The one study Hoffmann-La Roche leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT01995383Atherosclerosis · United States | 1 | Completed | Jun 2014 | 88 |
How it is read
Names in the registry
- “Baxdrostat”, 8 entries
- “CIN-107”, 7 entries
- “Baxdrostat/dapagliflozin”, 3 entries
- “baxdrostat”, 3 entries
- “RO6836191”, 3 entries
Conditions, from the studies’ own filings
- Hypertension, 15 studies
- Renal Insufficiency, Chronic, 4 studies
- Hyperaldosteronism, 2 studies
- Heart Failure, 1 study
- Atherosclerosis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.